Relationship among pathological changes in Liver tissues and level of serum HBV DNA, HBeAg and ALT of 194 patients with chronic hepatitis B.
- Author:
Deng-yun ZHAO
1
;
Ya-qin QIN
;
Xing-ming TANG
;
Gui-zhang LIU
;
Wei ZHENG
;
Hong-rong NONG
;
Jia-jun SONG
;
Qiu-yan XIE
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Alanine Transaminase; blood; DNA, Viral; blood; Female; Hepatitis B e Antigens; blood; Hepatitis B virus; genetics; immunology; physiology; Hepatitis B, Chronic; blood; pathology; virology; Host-Pathogen Interactions; Humans; Liver; pathology; virology; Male; Middle Aged; Young Adult
- From: Chinese Journal of Experimental and Clinical Virology 2007;21(1):35-37
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the relationships among pathological and immunohistochemical changes in liver tissues, and the HBeAg, HBV DNA, ALT level in the patients with chronic hepatitis B.
METHODSPathological and immunohistochemical examinations of liver tissue liver function tests, serum HBV and HBV DNA detection were performed in 194 patients with chronic hepatitis B.
RESULTSThere was significant difference between the serum HBeAg positive group and the negative group in G2, G3-4 S2, S3-4 in liver tissues; The serum HBV DNA level of the groups S0 and S1-4, and the hepatic activity index between the groups G0-1 and G2-4 were significantly different. And the hepatic HBcAg positive group and HBcAg negative group were significantly different too. There was no significant difference between the HBsAg level in liver tissues as "+" group and the "++ - +++" group. The pathological diagnosis as S1 or (and) G2 is respectively 28.57%, 53.33%, 80.15%, 77.88% among the four groups with normal-mild-moderate-severe elevated serum ALT level.
CONCLUSIONSerum HBV DNA correlated with HBcAg expression in liver tissue; the HBsAg level in liver tissues have no relationship with the serum HBV DNA level. The patients with low serum HBV DNA level may have high index of hepatic activity and hepatic fibrosis. Asymptomatic carriers and patients with low serum ALT level should be encouraged to accept liver biopsy. It can determine the degree of liver inflammation and fibrosis and timing of treatment.